Skip to main content
Black Diamond Therapeutics, Inc. logo

Black Diamond Therapeutics, Inc. — Investor Relations & Filings

Ticker · BDTX ISIN · US09203E1055 US Manufacturing
Filings indexed 461 across all filing types
Latest filing 2026-04-29 Annual Report
Country US United States of America
Listing US BDTX

About Black Diamond Therapeutics, Inc.

https://www.blackdiamondtherapeutics.co…

Black Diamond Therapeutics, Inc. is a clinical-stage precision oncology company developing MasterKey therapies. These therapies are designed to target families of oncogenic mutations in patients with genetically defined cancers. The company's approach aims to provide a single solution for multiple mutations, thereby expanding the addressable patient population. The therapies are engineered to overcome treatment resistance, minimize toxicities related to wild-type proteins, and be brain-penetrant to treat central nervous system diseases. Primary areas of focus include non-small cell lung cancer (NSCLC) and glioblastoma (GBM).

Recent filings

Filing Released Lang Actions
ARS - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
Annual Report
2026-04-29 English
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
Director's Dealing
2026-03-20 English
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
Director's Dealing
2026-03-20 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
4 Filing
Director's Dealing
2026-01-23 English
4 Filing
Director's Dealing
2026-01-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.